ATE76583T1 - Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. - Google Patents
Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.Info
- Publication number
- ATE76583T1 ATE76583T1 AT86309515T AT86309515T ATE76583T1 AT E76583 T1 ATE76583 T1 AT E76583T1 AT 86309515 T AT86309515 T AT 86309515T AT 86309515 T AT86309515 T AT 86309515T AT E76583 T1 ATE76583 T1 AT E76583T1
- Authority
- AT
- Austria
- Prior art keywords
- human ovarian
- ovarian cancer
- mammals
- monoclonal antibody
- methods
- Prior art date
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 8
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 4
- 229940051026 immunotoxin Drugs 0.000 abstract 4
- 230000002637 immunotoxin Effects 0.000 abstract 4
- 239000002596 immunotoxin Substances 0.000 abstract 4
- 231100000608 immunotoxin Toxicity 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80625685A | 1985-12-06 | 1985-12-06 | |
| EP86309515A EP0226418B1 (de) | 1985-12-06 | 1986-12-05 | Anti-Immuntoxine gegen menschlichen Eierstockkrebs und Verfahren zu deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE76583T1 true ATE76583T1 (de) | 1992-06-15 |
Family
ID=25193669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT86309515T ATE76583T1 (de) | 1985-12-06 | 1986-12-05 | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0226418B1 (de) |
| JP (1) | JPS62209098A (de) |
| AT (1) | ATE76583T1 (de) |
| CA (1) | CA1287578C (de) |
| DE (1) | DE3685485D1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806494A (en) * | 1986-07-24 | 1989-02-21 | The United States Of America As Represented By The Department Of Health & Human Services | Monoclonal antibody against ovarian cancer cells (OVB-3) |
| US4921790A (en) * | 1987-04-24 | 1990-05-01 | Research Corporation | Tumor specific assay for CA125 ovarian cancer antigen |
| EP0377657A1 (de) * | 1987-08-19 | 1990-07-18 | Centocor, Inc. | Menschliches ovarialtumor assoziertes antigen, das spezifisch ist für den antikörper ov-tl3 |
| IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5024834A (en) * | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
| WO1991002079A1 (en) * | 1989-07-31 | 1991-02-21 | The University Of British Columbia | Monoclonal antibodies against a tumor-associated antigen |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5843926A (ja) * | 1981-09-08 | 1983-03-14 | Suntory Ltd | 選択性制癌剤 |
| EP0121388B1 (de) * | 1983-03-30 | 1990-06-13 | Lilly Industries Limited | Immunoglobulinkonjugate |
-
1986
- 1986-12-05 CA CA000524645A patent/CA1287578C/en not_active Expired - Fee Related
- 1986-12-05 DE DE8686309515T patent/DE3685485D1/de not_active Expired - Fee Related
- 1986-12-05 EP EP86309515A patent/EP0226418B1/de not_active Expired - Lifetime
- 1986-12-05 AT AT86309515T patent/ATE76583T1/de active
- 1986-12-06 JP JP61289791A patent/JPS62209098A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62209098A (ja) | 1987-09-14 |
| EP0226418A2 (de) | 1987-06-24 |
| DE3685485D1 (de) | 1992-07-02 |
| EP0226418B1 (de) | 1992-05-27 |
| EP0226418A3 (en) | 1988-04-27 |
| CA1287578C (en) | 1991-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3686313D1 (de) | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. | |
| Nap et al. | Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen | |
| Irie et al. | Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. | |
| AU605771B2 (en) | Monoclanal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes | |
| GR1000712B (el) | Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα. | |
| DK499086D0 (da) | Konjugater af trichothecen og anvendelse af samme som terapeutisk substans | |
| ATE267610T1 (de) | Glykosylierte igg antikörper | |
| KR880700061A (ko) | 인체 암종양과 관련된 항원에 대한 단클론성 항체 | |
| EP0265500A4 (de) | Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren. | |
| IL148113A0 (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
| ATE71410T1 (de) | Tumorspezifische monoklonale antikoerper. | |
| EP0352722A3 (de) | Bindungstests für Adenocarcinoma-Antigen und Reagenzien | |
| ATE76583T1 (de) | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. | |
| LU90955I2 (en) | Reopro-fab fragment of chimeric monoclonal antibody 7 e3 | |
| DE59209776D1 (de) | Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| ATE131069T1 (de) | Composition comprising at least two different antibodies or fragments thereof. | |
| MY103231A (en) | Immunoglobulin conjugates | |
| Nilsson et al. | A human lymphoid cell line with an IgG‐like membrane component | |
| EP0380018A3 (en) | Rat monoclonal antibodies directed against human antigens and processes for preparation thereof | |
| KR880002540A (ko) | 암치료용 세포독성 결합체 | |
| Tsai et al. | Monoclonal Antibody to Human Osteosarcoma: A Novel M r 26,000 Protein Recognized by Murine Hybridoma TMMR-2 | |
| CA1315220C (en) | Preparation of monoclonal antibodies capable of reacting with human breast carcinoma cells | |
| Balint | Immune complexes with antiglobulin activity in sera of Moloney sarcoma-bearing rats | |
| Meenakshi et al. | Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation | |
| DE69229829D1 (de) | Tumorspezifischer monoklonaler antikörper 81av78 |